Atlas Trials

R-Pharm International, LLC

17 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch R-Pharm International, LLC

RecordFirmDate
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease (NCT07625384)R-Pharm International, LLC2026-05-18
Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE) (NCT07670546)R-Pharm International, LLC2025-06-11
Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers (NCT07206043)R-Pharm International, LLC2024-12-03
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT07553988)R-Pharm International, LLC2024-10-24
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD) (NCT05432960)R-Pharm International, LLC2023-12-01
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases (NCT06440746)R-Pharm International, LLC2023-08-23
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis (NCT07517575)R-Pharm International, LLC2023-03-17
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 (NCT04246762)R-Pharm International, LLC2021-11-16
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever (NCT05190991)R-Pharm International, LLC2021-10-05
Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine (NCT05092776)R-Pharm International, LLC2021-04-29
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis (NCT05673902)R-Pharm International, LLC2020-12-11
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) (NCT04380519)R-Pharm International, LLC2020-04-23
Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis (NCT04692766)R-Pharm International, LLC2020-02-12

Track R-Pharm International, LLC automatically

Every clearance here is in the API, with alerts when new ones post.